BioMarin Pharmaceutical Inc
Closed
SectorHealthcare
69.06 1.11
Overview
Share price change
24h
Min
63.23
Max
69.22
Income | -34M 106M |
|---|---|
Sales | -108M 766M |
P/E Sector Avg | 43.162 68.51 |
EPS | 0.76 |
Profit margin | 13.773 |
Employees | 3,221 |
EBITDA | 177M 173M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +40.73% upside |
Next Earnings | 26 Oct 2026 |
|---|
Market Cap | 1.2B 12B |
|---|---|
Previous open | 67.95 |
Previous close | 69.06 |
BioMarin Pharmaceutical Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
BioMarin Pharmaceutical Inc Forecast
Price Target
By TipRanks
40.73% upside
12 Months Forecast
Average 89.8 USD 40.73%
High 124 USD
Low 60 USD
Based on 20 Wall Street analysts offering 12 month price targets forBioMarin Pharmaceutical Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About BioMarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.
